The misrepresentation of high drug costs: Who is looking out for the patient?
"Drug prices are among the highest cost drivers in health care and action must be taken to manage those costs . . . . " 1 We're sure you have heard this before (and may even believe it). Indeed, in the recent past, there have been many reports, news items and government pronouncements about the high cost of drugs and the need to do something, as the current system is not sustainable. Did you ever wonder what they meant by "sustainable"? Would everything collapse if we spent a bit more on medication? A lot of people think so. On the other side, the question can be raised whether we want to sustain a dysfunctional, poorly rated health system by continuing to do the same things, the same way, at the same cost, instead of taking a more innovative approach more in line with public demand for major changes.
So what is the contribution of drugs to health care costs? Twenty-five percent? Thirty? Fifty? Actually, no, they make up only about 6% of public health expenditures (in 2014, total drug expenditures were 13.4%, but the public sector was 42% of this). The main cost drivers are physician and hospital expenditures, which are 90% covered by public funding. 2 Ironically, these aren't seen to be a threat to sustainability, even though expenditures are much higher and are increasing much more rapidly. 3 As for expenditures, with the expiration of patents and the exclusion of new drugs on benefit lists, the increase in drug expenditures has been 5% or less over the past decade, certainly less than the increase in physician and hospital expenditures. Private insurance and individuals are seeing much larger increases in expenditure as provinces offload responsibility (while crying the blues).
What are the implications of this misperception about drug costs?
We should be concerned about this misperception and its implications for our patients.
1. Our patients don't have access to many new efficacious therapies.
2. The government can use this as a "smoke screen" and implement restrictive drug policies and further shift costs to patients. Certainly, politicians faced with complaints of high drug expenses find it easier to promise to reduce prices than to deal with the real issue by initiating a drug program that removes financial barriers. 3. The government can avoid remunerating pharmacists for clinical services because "they are already spending too much on pharmacy stuff. "
What can we do about this?
This issue requires some real action by both individual practitioners and the organizations that represent them. What individual pharmacists can do:
1. Assess the patient's needs and write to their drug program to have patient access to benefits. Have the physician sign the letter as well. Be specific on the benefits to that individual patient. 2. If the benefit drugs are not included in the formulary, ask why they are excluded and request the evidence that the decision-makers are using (sometimes there is none). 3. Tell the patient that their drug benefit program is not acting in their best interest and invite them to research the situation and take action themselves. 4. Talk to your member of the Legislative Assembly about the lack of evidence, communication, bias in government decisions on drug benefits and the inaccuracy of high drug costs as the driver of health care costs. 5. Find out what your professional organizations are doing about this. If nothing, ask why.
What pharmacy organizations can do:
1. Take a strong stand on better patient access. 2. Circulate drug clinical guidelines to pharmacists (CPJ already does this, but it is important to highlight mismatches between evidence-based clinical practice guidelines and local formularies).
JOhNA.BAChyNsky,PhD ROssT.Tsuyuki,BsC(PhARM),PhARMD,MsC,FCshP,FACC EDITORIAL 3. In chain pharmacies, special interest groups can develop policy positions to submit to drug programs. 4. Assess drug programs and publicize those with a failing grade. 5. Partner with disease-based health charities to combine voices. 6. Clarify the meaning of pharmacists being the experts on drugs and what impact this has on health care.
Other things we can do:
1. Identify speakers to talk at meetings (political, community) to identify the problem (lack of access to new drugs and delays in appropriate therapy and their impact on long-term morbidity). 2. Identify regulations that cause problems and push for changes.
Stay up to date on national actions by the Canadian
Pharmacists Association on Pharmacare 2.0.
4. Meet with representatives of pharmaceutical companies (i.e., government affairs liaisons) to get more accurate information on issues. 5. Think about your professional responsibility to patients (duty of care). 6. Keep talking about this important issue! ■
